**TO THE EDITOR**

Transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) are central mediators of fibrosis, and their overexpression contributes to the pathophysiology of scleroderma, chiefly by inducing the overproduction of extracellular matrix proteins (ECM) by dermal fibroblasts ([@bib6]; [@bib11]; [@bib3]). TGF-β also promotes the differentiation of dermal fibroblasts into myofibroblasts, which are key mediators of scleroderma ([@bib1]). Thus, targeting this pathway is a reasonable strategy to treat a variety of fibrotic diseases including scleroderma, for which current treatment options are limited. Herein we explore the potential of novel mTOR inhibition as a means to block the pro-fibrotic effects of TGF-β. Recent studies have suggested a functional role of mTOR in fibrotic diseases and autoimmunity ([@bib9]; [@bib5]; [@bib12]; [@bib10]). This pathway is initiated by cytokines and growth factors that induce phosphorylation of Akt^(Thr308)^ and its downstream mediators mTORC1, p70S6K1, and 4E-BP1. In addition to mTORC1, mTOR is now known to comprise a second multi-protein complex, mTORC2, which positively regulates the activity of mTOR through phosphorylation of Akt^Ser473^ ([@bib2]). Blockade of mTORC1 has already been attempted as a treatment for scleroderma without much understanding about its molecular mechanism ([@bib5]; [@bib12]; [@bib14]). Such strategies focused only on mTORC1 and did not account for the contributions of mTORC2 ([@bib2]). To increase the effectiveness of mTOR blockade, dual inhibitors targeting both mTORC1 and mTORC2 have now been developed ([@bib2]). Herein, we demonstrate that dual mTOR blockade can more effectively inhibit the pro-fibrotic effects of TGF-β and PDGF. These have therapeutic implications for scleroderma and other TGF-β dominant fibrotic diseases.

Antiproliferative effect of OSI-027, a dual mTOR inhibitor
==========================================================

The antimitotic effects of mTOR inhibition were evaluated using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay. Normal human dermal fibroblasts (NHDFs) were incubated with PDGF, a known NHDF mitogen, and cultures were treated with either OSI-027 or the mTORC1 inhibitor rapamycin. OSI-027 was found to be more effective at inhibiting PDGF-induced NHDF proliferation compared with rapamycin (*P*\<0.05) ([Figure 1a](#fig1){ref-type="fig"}).

Expression of α-SMA, collagen I, and III
========================================

Apart from proliferating more, in response to TGF-β, NHDFs are known to differentiate into myofibroblasts and increase their production of ECM proteins. Thus, the expression of α-SMA (a marker of myofibroblasts) and the ECM-collagen I and III was determined by immunofluorescence microscopy (IF) following incubation with TGF-β ([@bib1]). In comparison with rapamycin, OSI-027 was more effective at inhibiting TGF-β-induced α-SMA (*P*\<0.01), collagen I (*P*\<0.01), and collagen III (*P*\<0.05) expression ([Figure 1b and c](#fig1){ref-type="fig"}). Similarly, by quantitative PCR (qPCR), OSI-027 was found to be more effective at inhibiting TGF-β-induced upregulation of ACTA2 (*P*\<0.005), COL1A1 (*P*\<0.005), and COL3A1 (*P*\<0.05) gene expression. OSI-027 was also able to reverse TGF-β-induced downregulation of MMP1 (*P*\<0.05) ([Figure 1d](#fig1){ref-type="fig"}).

Phosphorylation of mTOR kinases and Smad2
=========================================

The ability of PDGF and TGF-β to alter mTOR signaling was confirmed using a luminex-based cell-signaling assay. [Figure 1e and f](#fig1){ref-type="fig"} demonstrated that TGF-β and PDGF were able to induce significant phosphorylation of Akt^Ser473^ (representing mTORC2 activity) and mTOR^Ser2448^. As Smad signaling is critical for TGF-β-mediated induction of ECM ([@bib3]), we determined the effect of OSI-027 on phosphorylation of Smad2. We found that TGF-β-induced phosphorylation of Smad2 was effectively inhibited by OSI-027 (*P*\<0.05) ([Figure 1g](#fig1){ref-type="fig"}). This provides an underlying molecular mechanism for the antifibrotic effects of dual mTOR inhibition.

Expression of mTOR kinases in scleroderma
=========================================

On the basis of the *in vitro* data, we sought to evaluate whether mTOR was expressed in lesional skin of scleroderma patients. Immunohistochemical staining ([Figure 2a](#fig2){ref-type="fig"}) demonstrated elevated expression of pAkt^Ser473^, pmTOR^Ser2448^, and their respective total proteins in scleroderma compared with normal skin. Quantification of pAkt^Ser473^ was used as a surrogate for mTORC2 activity ([@bib2]).

Although there are few studies suggesting the antifibrotic properties of rapamycin, chiefly a mTORC1 inhibitor ([@bib9]; [@bib5]; [@bib12]; [@bib14]; [@bib13]), to date, there have been no detailed mechanistic studies on mTOR\'s role in TGF-β-mediated fibrotic pathways. Moreover, in cancer biology, it is becoming increasingly evident that targeting only mTORC1 does not completely inhibit this cascade ([Figure 2b](#fig2){ref-type="fig"}). To overcome this deficiency, dual mTOR (mTORC1/mTORC2) inhibitors have been developed----e.g. OSI-027 ([@bib2])----and are currently being evaluated in a phase I trial for solid cancers (<https://clinicaltrial.gov/ct2/show/NCT00698243?term=OSI-027&rank=1>). Herein using an *in vitro* system, we demonstrated the ability of dual mTOR inhibition to reverse TGF-β and PDGF-mediated fibrotic processes more efficiently compared with rapamycin and elucidated the underling molecular mechanism. Considering the crucial role of PDGF and TGF-β in the pathogenesis of scleroderma, our results support the development of dual mTOR inhibitors for scleroderma and other TGF-β-mediated fibrotic diseases.

Normal human dermal fibroblast (NHDF)
=====================================

Third to sixth passage NHDFs (ATCC PCS-201-012) were cultured at 37 °C per 5% CO~2~ in DMEM containing 10% FBS and 1% antibiotic-antimycotic. Cells were incubated in the presence or absence of PDGF (40 ng ml^−1^), TGF-β (5 ng ml^−1^) with or without rapamycin (10 nM), and OSI-027 (5 uM) for 3 days, which corresponded to their optimal concentrations. To measure proliferation, the MTT reagent was added and incubated at room temperature for 2 hours. Plates were read at 570 nm ([@bib4]).

Immunofluorescence microscopy (IF)
==================================

NHDFs were processed for IF as described ([@bib8]). The data are represented as adjusted integrated density using Image J (NIH, Bethesda, MD).

Luminex assay
=============

Expression of pAkt^Ser473^, pmTOR^Ser2448^, pSmad2^Ser465/467^, corresponding total proteins, and β-actin was determined using the Bio-Plex Pro cell signaling kit (Bio-Rad) ([@bib7]). The phospho-proteins were normalized to respective total-proteins and represented as adjusted median fluorescence intensity (MFI).

Quantitative PCR
================

RNA was extracted using the RNeasy plus mini kit (Qiagen) and integrity determined by Agilent 2200 TapeStation. Total RNA was reverse transcribed using iScript, and qPCR was performed using customized PrimePCR plates (Bio-Rad, Hercules, CA). Reference genes used for normalization were GAPDH and HPRT1. Data were analyzed using the Bio-Rad CFX manager software (Bio-Rad) and expressed as fold change.

Skin biopsy
===========

After obtaining IRB approved written informed consent, punch biopsies were obtained from three scleroderma patients with diffuse disease, and normal skin samples were obtained from discarded surgical skin.

Immunohistochemistry
====================

Serial sections were deparaffinized and rehydrated and then immersed in 10 mM sodium citrate buffer. After antigen retrieval, endogenous peroxidase activity was blocked, and 10% BSA was used to inhibit nonspecific binding. Sections were stained with antibodies with the following specificities----pAkt^Ser473^, total Akt, pmTOR^Ser2448^, and total mTOR. Stained tissues were incubated with a secondary antibody followed by ABC reagents and DAB (Vector Lab, Burlingame, CA). Toludine blue was used to counterstain.
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![**Comparative antifibrotic potential of OSI-027 and rapamycin.** NHDFs were pre-treated with OSI-027 (5 uM) or rapamycin (10 nM) for 2 hours followed by an addition of PDGF (40 ng ml^−1^) or TGF-β (5 ng ml^−1^) and incubated for 3 days. Proliferation was determined by the MTT assay (*n*=11). Immunofluorescence microscopy (IF, *n*=6) and qPCR (*n*=6) were conducted to determine the expression of α-SMA, collagen I, and collagen III at protein and mRNA level, respectively. (**a**) Scatter plot showing the antimitotic effect of OSI-027 and rapamycin on PDGF-stimulated NHDFs. OSI-027 showed significantly more antimitotic effect compared with rapamycin. (**b**) Representative image showing the effect of OSI-027 and rapamycin on expression of α-SMA, collagen I, and collagen III. (**c**) Bar diagram comparing the inhibitory effect of OSI-027 and rapamycin on TGF-β-induced expression of α-SMA, collagen I, and collagen III. (**d**) Bar diagram showing the effect of OSI-027 and rapamycin on α-SMA (ACTA2), collagen I, and collagen III genes. OSI-027 showed more inhibitory effect on these genes compared with rapamycin. (**e**--**g**) Phosphorylation of mTOR kinases with PDGF and TGF-β. Luminex-based cell signaling assay was performed with treated and untreated cell lysates to determine molecular mechanism of mTOR inhibitors as antifibrotic agent (*n*=5). Data are represented as adjusted median fluorescence intensity (MFI)=MFI of phospho protein/MFI of total protein. Bar diagram showing significant upregulation of pAkt^Ser473^ (represents mTORC2 activity), pmTOR^Ser2448^ wilth PDGF, and TGF-β and a significant inhibition of TGF-β-induced pSmad2 with OSI-027. Data are represented as Mean±SEM. All experiments were performed in triplicate. The Mann--Whitney *U*-test was performed to determine statistical significance. Scale bar=100 μm. MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; NHDF, normal human dermal fibroblast; PDGF, platelet derived growth factor; qPCR, quantitative PCR.](jid2015252f1){#fig1}

![**Differential expression of mTOR kinases in scleroderma and normal skin.** (**a**) Representative image showing the differential expression of mTORC1 (pmTOR) and mTORC2 (pAkt^Ser473^) in scleroderma and normal skin. Serial sections of scleroderma and normal skin tissues were stained with H&E, Masson\'s trichrome, pAkt^Ser473^, pmTOR^Ser2448^, Total Akt, and Total mTOR. Tissues were counterstained with toludine blue. Black arrow indicates the positively stained cells. (**b**) Schematic diagram depicting the underlying molecular mechanism of mTOR inhibitors as antifibrotic agents. Scale bar=100 μm.](jid2015252f2){#fig2}
